Agache, I., Rocha, C., Beltran, J., Song, Y., Posso, M., Solà, I., Alonso‐Coello, P., Akdis, C., Akdis, M., Canonica, G. W., Casale, T., Chivato, T., Corren, J., Del Giacco, S., Eiwegger, T., Firinu, D., Gern, J. E., Hamelmann, E., Hanania, N., Mäkelä, M., Martín, I. H., Nair, P., O'Mahony, L., Papadopoulos, N. G., Papi, A., Park, H., Pérez de Llano, L., Quirce, S., Sastre, J., Shamji, M., Schwarze, J., Canelo‐Aybar, C., Palomares, O., & Jutel, M. (2020). efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. Allergy, 75(5), 1043–1057. http://access.bl.uk/ark:/81055/vdc_100103792456.0x000048